Results 271 to 280 of about 291,218 (316)

Perforin Expression and Natural Killer-Cell Proportion as Biomarkers in Secondary Hemophagocytic Lymphohistiocytosis. [PDF]

Med Sci Monit
Wang J, Li X, Duan L, Yin G, Gao X, Qiu H, Xu J, Tian T.   +7 more
europepmc   +1 more source

Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy

Advanced Science, EarlyView.
A zinc/manganese (Zn/Mn)‐based metal‐organic framework (MOF) loaded with the STING agonist c‐di‐AMP diammonium (denoted AMP@Zn/Mn‐MOF) was developed to synergistically activate the cGAS‐STING pathway and induce immunogenic cell death. This nanoplatform reprograms the immunosuppressive tumor microenvironment, significantly enhancing anti‐PD‐L1 ...
Bingzi Zhu, Xiaodong Chen, Chang Xu, Xuehua Qian, Binglong Bai, Ji Lin, Wenhai Deng, Xiang Wang, Yuekai Cui, Shengsheng Zhao, Zuoliang Xie, Tao You, Yingpeng Huang, Xian Shen, Xufeng Lu, Weijian Sun   +15 more
wiley   +1 more source

The impact of CD81 on immune cells and clinical prognosis in multiple myeloma. [PDF]

Ann Hematol
Zhao Q, Lv M, Yan Q, Sun Y, Li F.
europepmc   +1 more source

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

Advanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo, Yingge Lv, Shuyu Huang, Chang Liu, Yan Ouyang, Bei Lan, Chenghao Xuan   +6 more
wiley   +1 more source

A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2- ORCHESTRA Project. [PDF]

Front Immunol
Ugel S, Gupta A, Spiteri G, Marchetti P, De Sanctis F, Wouters S, Konnova A, Monaco MGL, Carta A, Pezzani MD, Liviero F, Pavanello S, dell'Omo M, Fabiánová E, Bérešová J, Larese Filon F, Mauro M, Verlato G, Bronte V, Kumar-Singh S, Porru S.   +20 more
europepmc   +1 more source

A Subset of Pro‐inflammatory CXCL10+ LILRB2+ Macrophages Derives From Recipient Monocytes and Drives Renal Allograft Rejection

Advanced Science, EarlyView.
This study uncovers a recipient‐derived monocyte‐to‐macrophage trajectory that drives inflammation during kidney transplant rejection. Using over 150 000 single‐cell profiles and more than 850 biopsies, the authors identify CXCL10+ macrophages as key predictors of graft loss.
Alexis Varin, Jovanne Palvair, Lennie Messager, Jamal Bamoulid, Jasper Callemeyn, Mélanie Chaintreuil, Ludivine Dal Zuffo, Didier Ducloux, Imane Farhat, Mathieu Legendre, Laurent Martin, Florian Renosi, Xavier Roussel, Thibaut Vaulet, Maarten Naesens, Claire Tinel, Baptiste Lamarthée   +16 more
wiley   +1 more source

IL-7: a potential next-generation adjuvant for immune cell therapies. [PDF]

Front Immunol
Hotchkiss RS, DiPersio JF, Yee C, Pachynski RK, Van Den Brink MRM.   +4 more
europepmc   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, EarlyView.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source

Immuno-Hematological Profiles of HIV-Positive Patients Stratified by CD4⁺ T-Cell Counts: Toward Identifying a Surrogate Hematological Marker for Immune Suppression Severity. [PDF]

Diagnostics (Basel)
Arbaeen AF, Iqbal MS, Alsafi R, Al Masmoum H, Qadhi A, Alharbi W, Alharbi AM, Kedwa K, Albeshri MH, Alameer MS.   +9 more
europepmc   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source